Intersect ENT Inc (NASDAQ:XENT) CFO Jeryl L. Hilleman sold 12,833 shares of Intersect ENT stock in a transaction on Tuesday, April 3rd. The stock was sold at an average price of $37.66, for a total transaction of $483,290.78. Following the transaction, the chief financial officer now directly owns 36,265 shares of the company’s stock, valued at $1,365,739.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Intersect ENT stock opened at $36.60 on Friday. The stock has a market capitalization of $1,113.21, a PE ratio of -65.36 and a beta of 0.75. Intersect ENT Inc has a 52-week low of $15.90 and a 52-week high of $40.00.
Intersect ENT (NASDAQ:XENT) last announced its earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.06. The company had revenue of $29.53 million during the quarter, compared to analysts’ expectations of $29.45 million. Intersect ENT had a negative net margin of 16.99% and a negative return on equity of 14.40%. sell-side analysts forecast that Intersect ENT Inc will post -0.59 EPS for the current year.
Several institutional investors have recently made changes to their positions in the company. MetLife Investment Advisors LLC bought a new stake in shares of Intersect ENT in the fourth quarter valued at about $370,000. Wolverine Trading LLC bought a new stake in shares of Intersect ENT in the fourth quarter valued at about $341,000. Elkfork Partners LLC bought a new stake in shares of Intersect ENT in the fourth quarter valued at about $237,000. TIAA CREF Investment Management LLC boosted its position in shares of Intersect ENT by 7.7% in the fourth quarter. TIAA CREF Investment Management LLC now owns 137,428 shares of the medical equipment provider’s stock valued at $4,453,000 after acquiring an additional 9,792 shares during the period. Finally, Teachers Advisors LLC boosted its position in shares of Intersect ENT by 333.9% in the fourth quarter. Teachers Advisors LLC now owns 288,732 shares of the medical equipment provider’s stock valued at $9,355,000 after acquiring an additional 222,195 shares during the period. 84.49% of the stock is owned by institutional investors.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.